Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery ...

Additionally, two abstracts on another drug, AFM24, in combination with atezolizumab for treating non-small cell lung cancer (NSCLC) have been accepted for poster presentations. The oral ...

BioNTech to present clinical & pre-clinical data from mRNA and next-generation immuno-oncology priority programmes at AACR 2025: Mainz, Germany Saturday, April 26, 2025, 14:00 Hrs ...

Additionally, as previously announced, an oral presentation regarding Emi-Le will be given at the ESMO Breast Cancer 2025 Annual Congress in Munich, Germany on Thursday, May 15, 2025. This ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that two oral presentations and a poster presentation featuring data for the company’s NeXT ...